Multiple Sclerosis Clinical Trials in St Louis, Missouri
16 recruitingSt Louis, Missouri
Showing 1–16 of 16 trials
Recruiting
Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled99 locationsNCT06846281
Recruiting
Smoldering Inflammation in MS
Multiple Sclerosis
Washington University School of Medicine25 enrolled1 locationNCT06591429
Recruiting
Phase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Multiple Sclerosis
AstraZeneca24 enrolled19 locationsNCT07224373
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Multiple Sclerosis Spasticity
Celgene200 enrolled53 locationsNCT06782490
Recruiting
Phase 1Phase 2
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Primary Progressive Multiple Sclerosis
Tr1X, Inc.39 enrolled2 locationsNCT07477639
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Myasthenia GravisMultiple Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company120 enrolled35 locationsNCT06220201
Recruiting
Not Applicable
Functional Outcomes From Diets in Multiple Sclerosis
Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
University of Alabama at Birmingham100 enrolled2 locationsNCT05327322
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Multiple Sclerosis
Genentech, Inc.60 enrolled1 locationNCT07008378
Recruiting
Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting
Phase 2
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
Multiple Sclerosis
ModernaTX, Inc.180 enrolled17 locationsNCT06735248
Recruiting
This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.
Multiple Sclerosis
Washington University School of Medicine80 enrolled1 locationNCT07115017
Recruiting
Phase 2
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Multiple Sclerosis
Eli Lilly and Company200 enrolled50 locationsNCT06220669